Urogen Pharma Ltd.

Theracoat Ltd.

Marina Konorty

Asher Holzer

Dorit Daniel

Jaime De La Zerda

Yosh Dollberg

Nadav Malchi

Uri Shpolansky

Michael Mullerad

Dor Tal

Yossi Yavin

Gil Hakim

Omer Tsipori

Dalit Strauss-Ayali

Astar Friedman

Yulia Hionidi

Shpolansky Uri

Michal Jeshurun

A kit provides for sustained release of therapeutic agents for local treatment of cancer diseases by providing lyophilized Mitomycin C in a slowly releasing biocompatible hydrogel to be applied to affected tissue. The hydrogel comprises poloxamer 407, hydroxypropylmethylcellulose and water. A lyophilized composition comprises mitomycin C and urea as a bulking agent.

Material and method for treating cancer

Pharmaceutical compositions and methods for sustained release of therapeutic agents for local treatment of cancer diseases involve embedding lyophilized mitomycin C in a slowly releasing biocompatible hydrogel applied to affected tissue. The mitomycin C is lyophilized in a composition using urea as a bulking agent, and the mitomycin C and the bulking agent are present in a ratio of from about 1:7 to about 1:9 in the lyophilized pharmaceutical composition.

Described herein are compositions and methods for treating cancer of a body cavity, specifically urinary tract cancer, by way of a combination of at least two immunomodulatory agents, wherein one or more of the therapeutic agents are embedded in, and slowly released from, a biocompatible hydrogel composition.

Immunomodulating treatments of body cavities

Disclosed herein are materials, means and methods for sustained release of therapeutic agents for topical treatments. In particular, disclosed are means and methods for topical treatment of diseases of internal body cavities by embedding therapeutic agents in a slowly degrading biocompatible mixture applied to affected tissue.

Material and method for treating internal cavities

A hydrophilic biocompatible sustained-release material is disclosed. The material comprises amounts of Pluronic F-127, PEG-400, HPMC and water, effective to produce a composition of sufficiently low viscosity at room temperature to be injectable into an internal body cavity via a tube inserted within a urinary catheter. At body temperature, the material exhibits a much higher viscosity and will stably adhere to the internal surface of a body cavity. As the material dissolves, a therapeutic agent incorporated therein is slowly released to the body cavity, while the material itself is excreted from the body.

Provided herein are methods for treating cancer of a body cavity, including specifically urinary tract cancer, by way of at least one cell cycle regulator, and at least one anti-cancer drug for local treatment; wherein the therapeutic agents are embedded in, and slowly released from, a biocompatible hydrogel composition.

Growing community of inventors

Hertzyla, Israel

Marina Konorty